Trump administration touts billions in identified waste with much more work to be done

The administration reports identified waste and recovery efforts across federal programs, citing an early HUD review that found about $1.9 billion in misplaced funds and a White House claim of roughly $215 billion saved in the first year of the second term (~$1,335 per taxpayer). A HHS inspector general semiannual report flagged roughly $19 billion in waste, fraud and questionable health-care spending over six months, including a 640% surge in Medicare payments for bioengineered skin substitutes that prompted reimbursement caps expected to save over $9 billion. Officials are centralizing fraud detection at CMS and pursuing SNAP eligibility reforms after estimates that nearly six million recipients may not meet requirements, signaling continued oversight and potential policy changes but limited immediate market ramifications.

Analysis

Market structure: Aggressive CMS/HUD/USDA enforcement reallocates revenue away from niche, high-reimbursement suppliers (e.g., skin-substitute manufacturers) toward payors and compliance/analytics vendors. The HHS IG flagged ~$19B of problematic health spending in six months and CMS’ cap on skin substitutes targets ~$9B — a structural shock concentrated in small-cap device/specialty suppliers over the next 3–12 months. Expect payors (UNH, CVS, HUM) to see margin tailwinds while single-product device players lose pricing power and volume.

Risk assessment: Tail risks include legal challenges by suppliers, state-level cost-shifting to Medicaid, or political reversals if enforcement is disrupted; each could flip outcomes within 1–6 months. Second-order effects: providers may bill other codes or shift care settings, increasing acute care utilization and unpredictable capex needs for hospitals. Key catalysts are CMS rule releases, HHS IG reports and congressional hearings within the next 30–90 days.

Trade implications: Favor long exposure to large payors and government IT/analytics contractors (beneficiaries of “war room” demand) and short concentrated-exposure med-tech small caps whose revenue >20–30% tied to Medicare high-margin codes. Use defined-risk option structures (3–9 month spreads) around announcement windows; reweight into payors if CMS savings >$5B in first-year estimates. Bonds/FX: incremental $200B claimed savings is immaterial to rates short term but a sustained $100B+/yr program would mildly lower Treasury supply pressure over 12–24 months.

Contrarian: The consensus treats $215B claimed first-year savings as durable — it likely overstates recurring fiscal impact because many savings are timing adjustments or one-offs. Historical parallels (Medicare reimbursement adjustments 2007–2012) show device small caps often rebound after coding/legal cycles; therefore short-duration option shorts and selective pairs are preferable to multi-quarter naked shorts.

Key Decisions for Investors

• Establish a 2–3% portfolio long in large payors: buy UNH (UnitedHealth) and CVS (CVS Health) split 60/40 with a 6–12 month horizon to capture margin tailwinds from lower Medicare overpayments; consider 6–9 month 5–10% OTM call spreads to limit capital while keeping upside.
• Initiate a 0.5–1% short exposure to small-cap wound-care/device names heavily reliant on Medicare skin-substitute reimbursements (example: MDXG) using 3-month 15–25% OTM put spreads to limit downside if CMS caps expand; target names with >20–30% revenue from affected codes.
• Add 1–1.5% long in government analytics/IT contractors (example tickers: PLTR, BAH, LDOS) using 6–12 month calls or outright stock buys; accelerate to 2–3% if CMS/HHS contract awards for fraud-detection exceed $250M within 90 days.
• Use a pair trade: long UNH (2%) / short a basket of 3 small-cap device stocks (total 1%) for 3–6 months to capture relative-margin improvement; rebalance if CMS publishes final reimbursement rules reducing device code rates by >20%.